Introduction The use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy.
Introduction
Cold thermal injuries (i.e., frostbite, frostnip) from environmental exposure to cold (e.g., winter sports and military activities) are fairly common, with peripheral tissues such as the fingers and toes as well as unprotected ears, nose, and cheeks being the most prone sites. On the other hand, self-use [1] [2] [3] [4] , iatrogenic [5, 6] , and industrial exposurerelated [7] thermal burns due to cold are infrequent and are generally localized to the sites of exposure. Irrespective of the type of cold exposure, the scalp remains a rarely & Mario E. Lacouture lacoutum@mskcc.org described site for frostbite injuries, with only one published report (environmental exposure-related) of frostbite injury involving the scalp [8] .
In the 1970s, crushed ice in plastic bags was introduced as a promising modality for the prevention of chemotherapy-induced alopecia (CIA) [9, 10] . The methodology has evolved since, but the underlying principle remains scalp hypothermia, which induces cutaneous vasoconstriction and impedes the delivery of cytotoxic agents to hair follicles [11] , and possibly reduces apoptosis in hair follicle stem cells. In addition, the biochemical activity in cells lining the hair follicles is reduced, thus shielding them from cytotoxic drug toxicity. For the procedure, caps are maintained at very low temperatures just before application. This is generally achieved by the use of gel-filled caps (glycerin-based, ChemoCap TM /Elasto-Gel TM /Arctic TM ; crylon-based, Penguin TM [12, 13] ) that are pre-cooled (i.e. passive cooling) in a dry ice container or at -30°C to -40°C in a bio-medical freezer. Alternatively, refrigerated cooling systems that pump liquid coolant at a temperature of -5°C through a neoprene/silicone cap to achieve scalp temperatures of 18-22°C, such as the FDA-cleared Dignitana DigniCap feedback-controlled temperature regulated cooling system [14, 15] , or the Paxman Scalp Cooling System, currently under investigation in the US and approved for use elsewhere are also applied to the scalp for varying time periods before, during, and after cytotoxic chemotherapy infusions. Since cold caps and scalp cooling devices have shown efficacy without a demonstrated risk for increased scalp (micro-)metastases [16, 17] , their use is rapidly expanding.
The procedure is generally administered either by self/family member/friend, or by hired trained ''cappers'' (usually not medically trained), and is typically not covered by health insurance carriers. The hitherto reported adverse events (AEs) are mostly mild and include a feeling of coldness, headache, dizziness, pruritus, application-site discomfort, local pain, neck pain, sensation of heaviness, and claustrophobia [15, 16] . Herein, we expand this spectrum of AEs by describing cold thermal injuries on the scalp due to glycerol gel-based caps.
Materials and methods (case series)
Case 1 A 49-year-old female on adjuvant chemotherapy with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) for ER?/PR-/Her2?, stage IIA, invasive ductal carcinoma was using Penguin TM cold caps (made with hypo-allergenic plastics) for the prevention of CIA. Shortly after her third chemotherapy cycle/cold cap use, she developed erythema and numbness over the upper midforehead (near the hairline) and neighboring hair-bearing frontal scalp, with subsequent blistering and eventual crusting. She applied Neosporin Ò ointment locally to prevent infection, followed by twice daily applications of Bio-oil Ò . Three weeks later, however, partial alopecia ensued at the hairline (Fig. 1A) , while the scalp developed a much larger patch of alopecia (Fig. 1B) . Of note, the patient reported that during her third cold cap session, to protect against potential cold contact injury (frostbite) she had used a paper towel instead of the gauze and moleskin padding used previously. At her recent follow-up, around 5.5 months after the inciting event, mild post-inflammatory hyperpigmentation (forehead) and mild hair thinning (scalp) persisted.
Case 2 A 55-year-old female diagnosed with triplenegative, stage IIA, breast cancer, was treated with 4 cycles of adjuvant doxorubicin and cyclophosphamide, which resulted in near-complete alopecia of the scalp. She was subsequently started on paclitaxel and into the third cycle, she resorted to scalp cooling with the Elasto-Gel TM hypothermia cap (made with ''rubberized material'') for preventing further alopecia. While the patient felt well, a day later, she noticed a tense blister on the scalp. On exam, a large fluid-filled bulla was appreciated over an erythematous and edematous plaque on the left parietal scalp, with no signs of infection (Fig. 2) . The bulla was drained and topical clobetasol and silver sulfadiazine creams were recommended, which led to improve over the week. At her last follow-up (4 months later), mild hair thinning persisted.
Case 3 A 58-year-old female with ER ?/PR ?/Her2-, metastatic breast cancer was undergoing taxane-based chemotherapy (PH, paclitaxel and trastuzumab). To prevent CIA, she began using the Penguin cold caps with an intervening layer of moleskin over the entire scalp, starting with the first chemotherapy cycle. During her third cycle however, she experienced a hypersensitivity reaction to paclitaxel, and the infusion was terminated; the cold cap was removed and not used in the post-infusion period. The next day she received albumin-bound paclitaxel (Abraxane Ò ) chemotherapy, and approximately 2.5 weeks later, she developed diffuse alopecia associated with pruritus that progressively worsened over the following 2 weeks.
The patient, however, continued cold cap use, and to protect the scalp from cold injury, applied moleskin, a double-layered scarf, and tissue, under the cap. During her third albumin-bound paclitaxel infusion (4 weeks later), she felt extreme cold on her frontal scalp, which was associated with severe nausea. A few days later, there was blistering followed by crusting in the affected area that eventually resolved with alopecia (Fig. 3) . She again developed similar symptoms (with milder nausea) on the frontal scalp during her sixth cycle (10 weeks from initiation), which improved with aloe vera cream. Two months later, at her last follow-up, the hair had regrown to patient's satisfaction in the affected area.
Case 4 A 50-year-old female with ER?/PR?/Her2-, stage IA, invasive ductal carcinoma of the right breast, was started on chemotherapy (CMF, cyclophosphamide, methotrexate, and fluorouracil). To reduce the chances of developing CIA, she started using the Penguin TM cold caps, but shortly after the first cycle of chemotherapy/cold cap use, she developed tingling and pruritus, and eventually noticed crusting and desquamation on the crown of her scalp. It was described as a ''frostnip'' by her ''capper,'' but she consulted an outside dermatologist who diagnosed seborrheic dermatitis (resembling a cradle cap)-no medications were prescribed as the ''capper's instructions'' were not to use any topical medications. The symptoms resolved by her second chemotherapy cycle (in 2 weeks), and this time the capper placed a gauze between her scalp and the cap. She, however, went on to develop hair thinning and localized alopecia but was unable to recall when it had started. At her most recent follow-up (6 months after the first chemotherapy infusion), there was regrowth of hair in the affected area, although less dense and accompanied by sensitivity of the skin (Fig. 4) .
A summary of findings related to the use of cold caps in our patients is provided in Table 1 . 
Discussion
This is the first report of cold thermal injuries (frostbite) observed during cold cap use for the prevention of CIA. The scalp receives a rich blood supply from five arteries and numerous anastomoses making it an uncommon site for environmental frostbites, but it is not protected from cold thermal (contact) injury. According to the modern classification by depth [18] , freezing cold injuries can be superficial (first-and second-degree; erythema, edema, blisters) or deep (third-and fourth-degree; eschar, ulceration, gangrene). The latter involves tissues beneath the skin (e.g., muscle, tendon, nerve, blood vessel, and bone) and was fortunately not encountered in our patients, but the likelihood seems rare. We are monitoring the outcomes (resolution vs. permanent alopecia and/or scarring) in these patients throughout treatment and during long-term follow-up, in our cancer centerbased dermatology clinical programs (MSKCC, New York and Centro Paulista, Sao Paulo, Brazil).
The injuries in our series were superficial (i.e., limited to the skin), but it is noteworthy that they led to decreased hair regrowth (persistent alopecia) in three patients-a paradoxical outcome for an alopecia prevention strategy, the actual burden of which remains unknown. In addition, there are no evidence-based guidelines for the use of cold caps, which factor in parameters such as patient characteristics, chemotherapy regimen, scalp protection (e.g., surgical cap/dressings), duration of use (e.g., preand post-infusion cooling time), and hair type/amount (e.g., pre-existing alopecia). Conversely, scalp cooling devices (i.e. Dignicap, Paxman Scalp Cooling System) have been rigurously tested in clinical trials and their use has been subject to regulatory approval in the US and elsewhere.
Prolonged and direct exposure to sub-zero temperatures causes cutaneous vasoconstriction, anesthesia, endothelial cell injury with platelet aggregation and blood vessel thrombosis, and intracellular ice crystal formation [19, 20] . These events and their interplay lead to dehydration and protein modification in tissues, worsening tissue damage [21] , and eventually resulting in necrotic cell death. Needless to say, rewarming procedures could further aggravate the situation, given the potential for reperfusion injury [22] . However, the extent to which these could occur with the (improper) use of cold caps, the approach to effectively managing resultant injury, and whether cold cap use should then continue during subsequent chemotherapy cycles remain unanswered. In addition, the potential for developing permanent alopecia and scarring, and the resultant cosmetic disfigurement can be a huge concern.
A number of animal models have been used to study frostbite injury [19, [23] [24] [25] . Based on findings in a hairless mouse ear model, it appears that the minimum temperature necessary to produce consistent tissue necrosis is -4°C for 3 min. Although applied on hair-bearing skin (scalp) in humans, these caps are maintained at much lower temperatures (around -25°C) just before application. The consequences of inadvertent misapplication, therefore, could be grave. On the other hand, no instances of cold thermal injury have been reported with the refrigerated cooling systems (i.e. Dignicap and Paxman Scalp Cooling System), wherein the temperature is controlled. Thus, more research simulating in-human cold cap use must be undertaken, as the findings may permit streamlining of current usage protocols and the approach in clinic.
Some factors that place patients at risk for the development of frostbites in the general population include age, lifestyle (smoking), comorbidities (malnutrition/diabetes/ thyroid disease), concomitant medications (beta-blockers), and in patients undergoing scalp cooling it would be important to consider susceptible scalp areas (hair parting/ pre-existing alopecia), use of spacer material (e.g. Fig. 4 Mild persistent alopecia due to cold thermal injury in a 50-year-old female with stage IA, invasive ductal carcinoma, following the improper application of Penguin cold caps to prevent chemotherapy-induced alopecia. Note the hair thinning in a localized area of the scalp (crown), at 6 months after the first chemotherapy infusion/cold cap use moleskin/gauze), the duration of scalp cooling (both before/after chemotherapy), supportive staff experience, patient education (awareness of prolonged/direct application of cold material), and previous frostbite or temperature-sensitive disorders, among others. These need to be considered, for example, one study showed that only 20 min post-infusion time sufficed to prevent CIA in patients using a Scalp Cooling Device and receiving a docetaxel-based regimen [26] , which is dissimilar to the currently recommended 3-5 h. of post-infusion cooling time recommended by some cold cap manufacturers.
In conclusion, there is an urgent need to establish screening programs to exclude at-risk individuals and develop standardized treatment and education protocols based on the type of scalp cooling system used. With increasing use of a variety of innovative scalp cooling systems/methodologies, we anticipate that such unusual, yet preventable AEs may be more frequently encountered, especially in patients with pre-existing alopecia. Therefore, studies should focus on standardizing the application methodologies, target scalp temperatures to be achieved/maintained in hair-bearing areas, duration of cap usage, delivery mechanisms, continued use post-injury, patient surveys, and better identify the CIA-inducing chemotherapy regimens most amenable to scalp cooling. Proper patient/nurse education, and personnel training and certification procedures in cold cap administration need to be implemented. These are crucial for optimal clinical outcomes and to minimize impairments in health-related quality of life. 
